

09/617, 114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

AGHI et al.

Patent. No.: 6,770,632 B1

Issued: August 3, 2004

For: Folylpolyglutamyl Synthetase Gene

Transfer to Enhance Antifolate

Drug Sensitivity

Confirmation No.: 5851

Art Unit: 1636

Examiner: Nguyen, Quang

Atty. Docket: 0609.4830001/JAG/KRM

Request for Certificate of Correction Under 37 C.F.R. § 1.322

Attn: Certificate of Correction Branch

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Certificate AUG 27 2004 of Correction

It is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-captioned United States Patent. This Certificate of Correction is being requested due to mistakes which appear in the printed patent. These mistakes were made by the U.S. Patent and Trademark Office.

Specifically, the printed patent contains the following errors for which a Certificate of Correction is respectfully requested:

Requested Change

In the File History/ **Specification/Claims** Error

1. On Page 1, left column, please delete existing title Original specification, "Folypolyglutamyl Synthetase Gene Transfer To Enhance Antifolate" and insert therein --Folylpolyglutamyl Synthetase Gene Transfer to Enhance Antifolate Drug Sensitivity--.

page 1, lines 1-2.

PTO

- 2 -

Ì

2.	On Page 2, left column, under Other Publications, under author Garrow, T.A. et al., please delete "folylpoly (λ-glutamate)" and insert thereinfolylpoly (γ-glutamate)	Information Disclosure Statement and Form PTO-1449 (page 7), filed November 2, 2000.	PTO
3.	On Page 3, left column, under Other Publications, under author Taylor, S.M. et al., please delete "Folylpoly-μ-glutamate" and insert thereinFolylpoly-γ-glutamate	Information Disclosure Statement and Form PTO-1449 (page 16), filed November 2, 2000.	PTO
4.	On Column 29, claim no. 1, line 38, please delete "folypolyglutamyl" and insert thereinfolylpolyglutamyl	Supplemental Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003	PTO
5.	On Column 29, claim no. 1(a), line 41, please delete "encoding, operably" and insert thereinencoding FPGS, operably	Examiner's Amendment, page 2, last line, date mailed March 12, 2004	PTO
6.	On Column 29, claim no. 1(b), line 47, please delete "polyglumated" and insert thereinpolyglutamated	Supplemental Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003	PTO
7.	On Column 30, claim no. 15, line 24, please delete "bacteral" and insert thereinbacterial	Supplemental Amendment and Reply Under 37 C.F.R. § 1.116,	PTO
8.	On Column 30, claim no. 16, line 28, please delete "a".	filed December 22, 2003 Supplemental Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003	PTO
9.	On Column 30, claim no. 16, line 29, please delete "bacteral" and insert thereinbacterial	Supplemental Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003	PTO
10.	On Column 30, claim no. 20, line 41, please delete "folypolyglutamyl" and insert thereinfolylpolyglutamyl	Supplemental Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003	PTO

PTO

PTO

- 3 -

11. On Column 30, claim no. 20(a), lines 44-45, please Examiner's Amendment, delete "encoding, operably" and insert therein --encoding FPGS, operably--.

page 2, last line, date mailed March 12, 2004

12. On Column 30, claim no. 21, line 54, please delete Supplemental "inoculatin" and insert --inoculation--.

Amendment and Reply Under 37 C.F.R. § 1.116, filed December 22, 2003

Remarks

The above-noted corrections do not involve such changes in the patent as would constitute new matter or would require reexamination.

A completed Form PTO/SB/44 accompanies this request, with the above-noted corrections printed thereon. Accordingly, a Certificate of Correction is believed proper and issuance thereof is respectfully requested.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kacel Madawitz Karen R. Markowicz Agent for Patentees

Registration No. 36,351

Date: August 20, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

301144v1



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Corrwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Akcom Lawrence B. Bugaisky Donald J. Featherston Michael V. Messinge

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Albert L. Ferro* Donald R. Banowit Teresa U. Medler S Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala ore A. Wood

Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein* tason D. Eisenberg Michael D. Specht Andrea J. Karnage Tracy L. Muller LuAnne M. DeSantis Ann E. Summerfi Aric W. Ledford* Helene C. Carlson Timothy A. Doyle*
Gaby L. Longsworth
Lori A. Gordon* Nicole O. Dretar

Ted J. Ebersole Jyoti C. Iyer* Laura A. Vogel

Registered Patent Agents • Karen R. Markowicz Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Aaron L. Schwartz Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott

Attn: Certificate Of Correction Branch

Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

Admitted only in Maryland Admitted only in Virginia Practice Limited to Federal Agencies

August 20, 2004

WRITER'S DIRECT NUMBER: (202) 772-8637 INTERNET ADDRESS: KARENM@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent No. 6,770,632 B1

Issue Date: August 3, 2004

For: Folylpolyglutamyl Synthetase Gene Transfer to Enhance Antifolate

Drug Sensitivity

Patentees:

AGHI et al.

Our Ref:

0609.4830001/JAG/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Request for Certificate of Correction Under 37 C.F.R. § 1.322;
- 2. Certificate of Correction (PTO/SB/44); and
- 3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents August 20, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Karen R. Markowicz

Agent for Patentees

Registration No. 36,351

KRM/pcd Encls.

301959v1

Sterne, Kessler, Goldstein & Fox P.L.L.c. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.: 6,770,632 B1

DATED: August 3, 2004

INVENTORS: Aghi et al.

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

- On Page 1, left column, please delete existing title "Folypolyglutamyl Synthetase

 Gene Transfer To Enhance Antifolate" and insert therein

 --Folylpolyglutamyl Synthetase Gene Transfer to Enhance Antifolate Drug

 Sensitivity--.
- On Page 2, left column, under Other Publications, under author Garrow, T.A. et al., please delete "folylpoly (λ-glutamate)" and insert therein --folylpoly (γ-glutamate)--.
- On Page 3, left column, under Other Publications, under author Taylor, S.M. et al., please delete "Folylpoly-µ-glutamate" and insert therein --Folylpoly-γ-glutamate--.
- On Column 29, claim no. 1, line 38, please delete "folypolyglutamyl" and insert therein --folylpolyglutamyl--.
- On Column 29, claim no. 1(a), line 41, please delete "encoding, operably" and insert therein --encoding FPGS, operably--.

MAILING ADDRESS OF SENDER:

Sterne, Kessler, Goldstein & Fox P.L.L.C. 1100 New York Avenue, N.W. Washington, DC 20005-3934 (202) 371-2600

301061v1

PATENT NO. <u>6,770,632 B1</u>

No. of additional copies

Page 1 of 2

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

- On Column 29, claim no. 1(b), line 47, please delete "polyglumated" and insert therein --polyglutamated--.
- On Column 30, claim no. 15, line 24, please delete "bacteral" and insert therein --bacterial--.
- On Column 30, claim no. 16, line 28, please delete "a".
- On Column 30, claim no. 16, line 29, please delete "bacteral" and insert therein --bacterial--.
- On Column 30, claim no. 20, line 41, please delete "folypolyglutamyl" and insert therein --folylpolyglutamyl--.
- On Column 30, claim no. 20(a), lines 44-45, please delete "encoding, operably" and insert therein --encoding FPGS, operably--.
- On Column 30, claim no. 21, line 54, please delete "inoculatin" and insert --inoculation--.

MAILING ADDRESS OF SENDER:

Sterne, Kessler, Goldstein & Fox P.L.L.C. 1100 New York Avenue, N.W. Washington, DC 20005-3934 (202) 371-2600

301061v1

PATENT NO. 6,770,632 B1

No. of additional copies

Page 2 of 2

This collection of information is required by 37 CFR 1.322, 1.323 and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.